Association of Vitamin K epoxide reductase complex 1 (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient population
Authors:
- Joyce H.S. YouJYJoyce H.S. You
- Mark J. RiederMRMark J. Rieder
- Federico M. FarinFFFederico M. Farin
- Hui-Wen WilkersonHWHui-Wen Wilkerson
- David K. BloughDBDavid K. Blough
- Gregory ChengGCGregory Cheng
- Allan E. RettieARAllan E. Rettie
- 1 October 2005
- journal article
- research article
- Published by Wolters Kluwer Health in Pharmacogenetics and Genomics
- Vol. 15 (10) , 687-691
Abstract
To evaluate the association of VKORC1 genetic variants with warfarin dose requirements in a Hong Kong Chinese patient population. A retrospective study of Hong Kong Chinese patients chronically maintained on warfarin was conducted. Single nucleotide polymorphisms (SNPs) in VKORC1 and CYP2C9 were genotyped. Stable warfarin dose data were retrieved from patient medical records. Sixty-nine patients were included in the analysis. VKORC1 haplotypes H1 (group A) and H7 (group B) were most common, accounting for 86% and 13% of all haplotypic variation in this cohort. Patients carrying at least one copy of a VKORC1 group B haplotype (n=16) required a significantly higher stable warfarin dose (5.17±1.53 mg/day) than patients that were homozygous for group A haplotypes (n=53; 2.93±1.22 mg; P<0.001). In the VKORC1 A/A group, four patients (5.8%) were heterozygous for CYP2C9*3 and had a lower dose requirement (1.94±0.43 mg) than patients that exhibited the CYP2C9 *1/*1 genotype (3.01±1.23 mg), P=0.004. In multivariate analysis, VKORC1 and CYP2C9 explained 31% and 7.9% of the variability in warfarin dose, respectively. VKORC1 genotype is the dominant genetic influence on inter-individual variability in warfarin dose in Hong Kong Chinese. The lower mean dose of warfarin in Chinese, relative to Europeans, appears to be a reflection of their preponderance of the ‘low-dose’ VKORC1 H1/H1 (homozygous group A) genotype.Keywords
This publication has 15 references indexed in Scilit:
- Effect ofVKORC1Haplotypes on Transcriptional Regulation and Warfarin DoseNew England Journal of Medicine, 2005
- A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarinBlood, 2005
- Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2Nature, 2004
- Identification of the gene for vitamin K epoxide reductaseNature, 2004
- Association Between CYP2C9 Genetic Variants and Anticoagulation-Related Outcomes During Warfarin TherapyJAMA, 2002
- Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human dataPharmacogenetics, 2002
- Long-Term Treatment with Warfarin in Chinese PopulationAnnals of Pharmacotherapy, 2000
- Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatmentBlood, 2000
- Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complicationsThe Lancet, 1999
- Factors determining the maintenance dose of warfarin in Chinese patientsQJM: An International Journal of Medicine, 1996